Clinical Trial Update: Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for dasatinib in relapsed or refractory non-Hodgkin's lymphoma across Phase 1 and Phase 2, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: University of Nebraska | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-01